OncoSil Medical
Company Details
Status: Public
Employees: 11-50
Location:
Level 5, 7 Eden Park Drive Macquarie Park, Sydney, NSW 2113, AU
Type:
sample
sample
sample
Technology:
sample
sample
sample
About: OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy.
OncoSil Medical's lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹.
We believe in our technology and its ability to have a truly positive impact in Oncology.
OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications.
Website link: oncosil.com
References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
OncoSil Medical | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.